LON:PYC Physiomics (PYC) Share Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free PYC Stock Alerts GBX 1.50 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 1.44▼ 1.5750-Day Range 1.10▼ 1.5652-Week Range 0.90▼ 3.29Volume195,426 shsAverage Volume643,240 shsMarket Capitalization£2.03 millionP/E RatioN/ADividend Yield6.20%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Physiomics alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Physiomics Stock (LON:PYC)Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.Read More PYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYC Stock News HeadlinesApril 18, 2024 | americanbankingnews.comPhysiomics (LON:PYC) Stock Crosses Below 50 Day Moving Average of $1.31February 6, 2024 | lse.co.ukSMALL-CAP WINNERS & LOSERS: CMC Markets up amid cost savings actionApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.January 22, 2024 | lse.co.ukPhysiomics appoints COO Sargent as new CEO; completes restructuringJanuary 13, 2024 | morningstar.comPYC Therapeutics Ltd PYCNovember 15, 2023 | finance.yahoo.comSome Shareholders May Object To A Pay Rise For Physiomics Plc's (LON:PYC) CEO This YearNovember 10, 2023 | lse.co.ukPhysiomics gets UK government grant for oncology dosing tool projectSeptember 30, 2023 | finance.yahoo.comPhysiomics Full Year 2023 Earnings: Revenues DisappointApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 4, 2023 | marketwatch.comPhysiomics Names Peter Sargent as New COOAugust 31, 2023 | marketwatch.comPhysiomics Wins Further Contract With Merck KGaAJune 27, 2023 | marketwatch.comPhysiomics Raises GBP335,000 to Fund Growth OpportunitiesMay 31, 2023 | lse.co.ukPhysiomics to work with University of Sheffield on cancer researchMay 23, 2023 | marketwatch.comPhysiomics Shares Fall After FY 2023 Income Guidance CutApril 4, 2023 | marketwatch.comPhysiomics Shares Tumble After on Expectation of FY 2023 Income SlipMarch 7, 2023 | marketwatch.comPhysiomics 1H Pretax Loss Widened on Staff CostsOctober 12, 2022 | marketwatch.comPhysiomics Gets Contract With Cancer Research UKSeptember 8, 2022 | reuters.comPYSM.L - Physiomics Plc | Stock Price & Latest News | ReutersApril 8, 2022 | marketwatch.comPhysiomics Awarded Contract by French Pharmaceutical Company ServierDecember 13, 2021 | marketwatch.comPhysiomics Signs New Agreements With Merck KGaA for GBP300,000See More Headlines Receive PYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Physiomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:PYC CUSIPN/A CIKN/A Webwww.physiomics-plc.com Phone+44-1865-784980FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-70.32% Pretax MarginN/A Return on Equity-62.94% Return on Assets-37.22% Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.48 Sales & Book Value Annual Sales£900,707.00 Price / Sales2.26 Cash FlowGBX 0.36 per share Price / Cash Flow4.21 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares135,470,000Free FloatN/AMarket Cap£2.03 million OptionableNot Optionable Beta1.78 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Christophe D. Chassagnole Ph.D. (Age 54)Chief Scientific Officer & Executive Director Comp: $87.48kDr. Peter Joseph Sargent (Age 46)CEO, COO & Director Prof. David FellCo-Founder & Member of Scientific Advisory BoardMr. Anthony Louis Clayden ACA (Age 56)BSc (Hons), MSI, Head of Finance & Company Secretary Ms. Hayley CloseHead of Business DevelopmentDr. Venkata PutchaHead of BiostatisticsDr. Mark Middleton M.D.Ph.D., Consultant & Member of Scientific Advisory BoardDr. Robert Jackson Ph.D. (Age 80)Consultant & Member of Scientific Advisory Board More ExecutivesKey CompetitorsEvgen PharmaLON:EVGReNeuron GroupLON:RENENuformixLON:NFXSalvaRx GroupLON:SALVPort Erin Biopharma InvestmentsLON:PEBIView All Competitors PYC Stock Analysis - Frequently Asked Questions How have PYC shares performed in 2024? Physiomics' stock was trading at GBX 1.60 at the start of the year. Since then, PYC stock has decreased by 6.3% and is now trading at GBX 1.50. View the best growth stocks for 2024 here. How were Physiomics' earnings last quarter? Physiomics Plc (LON:PYC) released its earnings results on Wednesday, September, 30th. The company reported ($0.09) EPS for the quarter. Physiomics had a negative trailing twelve-month return on equity of 62.94% and a negative net margin of 70.32%. What other stocks do shareholders of Physiomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Physiomics investors own include Andalas Energy and Power (ADL), Uranium Energy (UEC), Tavistock Investments (TAVI), Sorrento Therapeutics (SRNE), Photonstar Led Group (PSL), IGas Energy (IGAS) and Hertz Global (HTZ). How do I buy shares of Physiomics? Shares of PYC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:PYC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Physiomics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
